Showing results (11-20 of 165) with videos related to
Sort By:
Pageof 17
Expert Review of Hematology|July 5, 2022
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinibChandan Saha, Claire HarrisonTherapeutic Advances in Hematology|April 23, 2013
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for cliniciansClaire Harrison, Alessandro M VannucchiBest Practice & Research. Clinical Haematology|September 6, 2014
How many JAK inhibitors in myelofibrosis?Bruna Velosa Ferreira, Claire HarrisonExpert Opinion on Pharmacotherapy|May 8, 2026
Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitorsIman Al Noumani, Claire HarrisonCurrent Hematologic Malignancy Reports|May 17, 2023
Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of MyelofibrosisGuadalupe Ferreira Gomes, Claire HarrisonAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasmsClodagh Keohane, Ruben Mesa, Claire HarrisonBlood|December 25, 2023
How I treat myeloproliferative neoplasms in pregnancySusan Robinson, Monica Ragheb, Claire HarrisonExpert Opinion on Drug Safety|June 5, 2014
Safety evaluation of ruxolitinib for treating myelofibrosisSofia Galli, Donal McLornan, Claire HarrisonCritical Care (London, England)|March 30, 2010
New versus old blood - the debate continuesJohn Laurie, Duncan Wyncoll, Claire HarrisonExpert Review of Hematology|September 8, 2015
The use of JAK inhibitors for low-risk myelofibrosisSamah Alimam, Donal McLornan, Claire HarrisonPageof 17